Operational Costs Compared: SG&A Analysis of GSK plc and ImmunityBio, Inc.

A Decade of SG&A: GSK plc vs. ImmunityBio, Inc.

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, GSK plc and ImmunityBio, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. GSK plc, a stalwart in the industry, consistently reported SG&A expenses averaging around $9.8 billion annually. This reflects a stable operational strategy, with a notable peak in 2020 at approximately $11.5 billion, before a slight dip in 2022.

Conversely, ImmunityBio, Inc., a burgeoning biotech firm, exhibited a dynamic growth pattern. Starting with a modest $4.3 million in 2014, their SG&A expenses surged to over $226 million by 2015, marking a staggering increase. This trend underscores ImmunityBio's aggressive expansion and investment in operational capabilities. As the industry braces for future challenges, these insights into SG&A trends offer a glimpse into the strategic priorities of these two distinct players.